Senti Bio to Participate in Upcoming Investor Conferences
September 03, 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.
Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202
August 05, 2024 08:05 ET
|
Senti Biosciences, Inc.
Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13, 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 09, 2024 16:05 ET
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
March 21, 2024 16:05 ET
|
Senti Biosciences, Inc.
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated...
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
March 22, 2023 17:09 ET
|
Senti Biosciences, Inc.
- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - -...
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
March 14, 2023 16:35 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces New Employment Inducement Grants
October 28, 2022 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...